Skip to main content
Journal cover image

Except for Robust Outliers, Rapamycin Increases Lesion Burden in a Murine Model of Cerebral Cavernous Malformations.

Publication ,  Journal Article
Alcazar-Felix, RJ; Shenkar, R; Benavides, CR; Bindal, A; Srinath, A; Li, Y; Kinkade, S; Terranova, T; DeBose-Scarlett, E; Lightle, R; Cruz, DV ...
Published in: Transl Stroke Res
July 9, 2024

Cerebral cavernous malformation (CCM) is a hemorrhagic cerebrovascular disease where lesions develop in the setting of endothelial mutations of CCM genes, with many cases also harboring somatic PIK3CA gain of function (GOF) mutations. Rapamycin, an mTORC1 inhibitor, inhibited progression of murine CCM lesions driven by Ccm gene loss and Pik3ca GOF, but it remains unknown if rapamycin is beneficial in the absence of induction of Pik3ca GOF. We investigated the effect of rapamycin at three clinically relevant doses on lesion development in the Ccm3-/-PDGFb-icreERPositive murine model of familial CCM disease, without induction of Pik3ca GOF. Lesion burden, attrition, and acute and chronic hemorrhaging were compared between placebo and rapamycin-treated mice. Plasma miRNome was compared to identify potential biomarkers of rapamycin response. Outlier, exceptionally large CCM lesions (> 2 SD above the mean lesion burden) were exclusively observed in the placebo group. Rapamycin, across all dosages, may have prevented the emergence of large outlier lesions. Yet rapamycin also appeared to exacerbate mean lesion burden of surviving mice when outliers were excluded, increased attrition, and did not alter hemorrhage. miR-30c-2-3p, decreased in rapamycin-treated mouse plasma, has gene targets in PI3K/AKT and mTOR signaling. Progression of outlier lesions in a familial CCM model may have been halted by rapamycin treatment, at the potential expense of increased mean lesion burden and increased attrition. If confirmed, this can have implications for potential rapamycin treatment of familial CCM disease, where lesion development may not be driven by PIK3CA GOF. Further studies are necessary to determine specific pathways that mediate potential beneficial and detrimental effects of rapamycin treatment, and whether somatic PIK3CA mutations drive particularly aggressive lesions.

Duke Scholars

Published In

Transl Stroke Res

DOI

EISSN

1868-601X

Publication Date

July 9, 2024

Location

United States

Related Subject Headings

  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1109 Neurosciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Alcazar-Felix, R. J., Shenkar, R., Benavides, C. R., Bindal, A., Srinath, A., Li, Y., … Awad, I. A. (2024). Except for Robust Outliers, Rapamycin Increases Lesion Burden in a Murine Model of Cerebral Cavernous Malformations. Transl Stroke Res. https://doi.org/10.1007/s12975-024-01270-9
Alcazar-Felix, Roberto J., Robert Shenkar, Christian R. Benavides, Akash Bindal, Abhinav Srinath, Ying Li, Serena Kinkade, et al. “Except for Robust Outliers, Rapamycin Increases Lesion Burden in a Murine Model of Cerebral Cavernous Malformations.Transl Stroke Res, July 9, 2024. https://doi.org/10.1007/s12975-024-01270-9.
Alcazar-Felix RJ, Shenkar R, Benavides CR, Bindal A, Srinath A, Li Y, et al. Except for Robust Outliers, Rapamycin Increases Lesion Burden in a Murine Model of Cerebral Cavernous Malformations. Transl Stroke Res. 2024 Jul 9;
Alcazar-Felix, Roberto J., et al. “Except for Robust Outliers, Rapamycin Increases Lesion Burden in a Murine Model of Cerebral Cavernous Malformations.Transl Stroke Res, July 2024. Pubmed, doi:10.1007/s12975-024-01270-9.
Alcazar-Felix RJ, Shenkar R, Benavides CR, Bindal A, Srinath A, Li Y, Kinkade S, Terranova T, DeBose-Scarlett E, Lightle R, DeBiasse D, Almazroue H, Cruz DV, Romanos S, Jhaveri A, Koskimäki J, Hage S, Bennett C, Girard R, Marchuk DA, Awad IA. Except for Robust Outliers, Rapamycin Increases Lesion Burden in a Murine Model of Cerebral Cavernous Malformations. Transl Stroke Res. 2024 Jul 9;
Journal cover image

Published In

Transl Stroke Res

DOI

EISSN

1868-601X

Publication Date

July 9, 2024

Location

United States

Related Subject Headings

  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1109 Neurosciences
  • 1103 Clinical Sciences